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Abstract: The construction and characterization of a new ion-selective electrode for the 
determination of the antipsychotic ziprasidone in mixed solvents is presented. The electrode 
contains a plasticized polymeric membrane based on a ziprasidone-tetraphenylborate  
ion-exchanger. The influence of membrane composition on the electrode response towards 
ziprasidone in hydroalcoholic solutions was studied. The electrode displayed a stable 
response in a 2:3 (v/v) methanol/water medium from a ziprasidone concentration of   
3 × 10
−6 M with a fast response time of less than 20 s. The electrode also showed good 
selectivity towards ziprasidone over common inorganic and organic compounds and 
several species with pharmacological activity. The electrode was successfully applied to 
the determination of ziprasidone in pharmaceuticals and human urine and serum.  




Many drugs are very hydrophobic and consequently poorly soluble in water, resulting in problems 
that may affect different fields of pharmaceutical science. The use of aqueous mixed solvents to increase 
the solubility of these drugs is one of the oldest, most powerful and widely used methods to address 
this issue [1].  




The application of ion selective electrodes in mixed solvents involves a series of problems 
concerning membrane selection and the measuring technique to be used. However, potentiometric 
studies in these media have opened up new possibilities for analytical and thermodynamic fields based 
on the data obtained [2,3]. 
A thorough literature search revealed little information on the use of ion- selective electrodes (ISEs) 
based on plasticized polymeric membranes in mixed solvents. This is probably because the membrane 
components should exhibit low leaching into the sample solutions. Despite this, some authors have 
succeeded in using plasticized polymeric membrane ISEs for determining metal ions [4-24], alkaline 
and alkaline-earth ions [25], monohydrogen phosphate [26], chromate ions [27] and surfactants [28,29] 
in mixed solvents.  
Ziprasidone (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazin-yl ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, 
ZPD, Figure 1), is a antipsychotic agent indicated for the treatment of schizophrenia, bipolar disorder and 
acute mania because of its affinity for serotonin (5HT2A) and dopamine (D2) receptors [30]. The 
therapeutic importance of this drug requires the development of sensitive and rapid analytical methods 
for its determination in pharmaceutical and clinical analysis. A review of the literature showed that 
several analytical methods have been described in this respect, including spectrophotometric [31-33], 
thin layer densitometry [34], capillary electrophoresis [35], voltammetric [36] and chromatographic [37-41] 
methods. However, to our knowledge, there is no ISE to determine ZPD. A possible reason for this 
could be the low solubility of ZPD in water, which makes it necessary to use non-aqueous or mixed 
solvents.  
Figure 1. Ziprasidone. 
 
Since potentiometry with ISEs offers many advantages, among them simple design and operation, 
low cost, fast response and the possibility of automation, the aim of the present work was to develop a 
potentiometric selective electrode for ZPD determination which could be used in mixed solvents for 
application in pharmaceutical and clinical analysis. 
2. Experimental Section  
2.1. Apparatus  
Potentials were measured with an Orion 960 Autochemistry System (Thermo-Orion, Cambridge, 
MA, USA), the recorder output of which was connected to a personal computer via a DGH 
Corporation 1121 module analogue-to-digital converter (Manchester, UK). An Orion 90–02 double 
junction silver-silver chloride reference electrode containing a 10% (v/v) solution of KNO3 in the outer 












2.2. Reagents and Solutions 
High molecular weight poly(vinyl chloride) (PVC), 2-nitrophenyl octyl ether (NPOE),   
bis(2-ethylhexyl) sebacate (DOS), and tetrahydrofuran (THF) were Selectophore products from Fluka 
(Munich, Germany). Sodium tetraphenylborate (NaTPB) was purchased from Sigma (Munich, 
Germany). Ziprasidone hydrochloride powder was kindly provided by Pfizer Laboratories (New York, 
USA). All other reagents used were of analytical reagent grade and Milli-Q water was used 
throughout. Ac
−/HAc buffer of pH 4.6 and 2 × 10
−1 M total concentration was used. 
A 4 × 10
−3 M ziprasidone hydrochloride standard solution was prepared by dissolving 0.0467 g of 
ziprasidone hydrochloride in 25 mL of methanol. Working solutions (8 × 10
−4 M to 1.6 × 10
−6 M) were 
prepared by diluting appropriate volumes of the standard solution with 15 mL of Ac
−/HAc buffer of  
pH 4.6 and methanol to a final volume of 25 mL in a calibrated flask. 
For the selectivity study, 4 × 10
−3 M solutions of amoxicillin, carbamazepine, cimetidine, 
clomipramine hydrochloride, diclofenac sodium, fluoxetine hydrochloride, furosemide, haloperidol, 
lansoprazol, lorazepan, ranitidine, ofloxacine and tenoxicam were prepared by dissolving suitable 
amounts of the corresponding drug in methanol. 
Dosage forms of ziprasidone for testing: Zeldox capsules (Pfizer Lb., Madrid, Spain) containing 
20 mg of ziprasidone hydrochloride with lactose monohydrate, starch, magnesium stereate, gelatine, 
dioxidum of titanium (E171) and indigotine (E132) up to total capsule weight; Zeldox powder for 
injectable solution containing 20 mg of ziprasidone mesylate and sodium sulfobutylether-β-cyclo-dextrin 
up to total vial powder weight. 
2.3. Ion-Exchanger Preparation 
The ion-exchanger (ZPD-TPB) was prepared by mixing 10 mL of 4 × 10
−3 M ZPD with 10 mL of a 
4 × 10
−3 M NaTPB aqueous solution. The mixture was filtered through a porosity-4 sintered glass 
crucible. The residue was washed with 1:1 (v/v) methanol/water solution until no chloride ion was 
detected in the washing solution and was then dried at room temperature. 
2.4. Construction and Conditioning of the Electrode 
The selected membrane was prepared by dissolving 3.0 mg of ZPD-TPB, 100 mg of PVC and 
200 mg of NPOE in 3 mL of THF. This solution was poured into a Fluka glass ring (inner diameter 
28 mm, height 30 mm) on a Fluka glass plate. The solution was allowed to evaporate overnight.   
A 7-mm diameter piece was cut out with a Fluka punch for ion-selective membranes and incorporated 
into a Fluka electrode body ISE containing 1 × 10
−2 M KCl and 8 × 10
−5 M ZPD saturated with AgCl 
as the internal filling solution. The electrode was conditioned by soaking with constant stirring in 
8 × 10
−5 M ZPD working solution until the electrode gave a constant potential. When not in use, the 
electrode was kept immersed in the same solution. 
2.5. Calibration of the Electrode 
The ZPD-selective electrode and reference electrode were immersed in any of the working ZPD 




potentials were then plotted vs. logarithmic values of ZPD concentration and the calibration parameters 
were calculated by fitting the calibration data to Equation (1): 
ܧൌܧ ଴ ൅ܵ ݈ ݋ ݃ ሺ ܮ ܱ ܦ൅ܥ ௓௉஽ሻ (1) 
where E is the potential of the cell, E
0 is the standard potential, S and LOD are the slope and the limit 
of detection of the electrode, respectively. 
For the dynamic response studies a dynamic calibration of the electrode was made by adding, while 
stirring, adequate small volumes by micropipette of the ZPD standard solution to 25 mL of a 2:3 (v/v) 
methanol/pH buffer solution to cover the concentration range from 1.6 × 10
−6 to 1.6 × 10
−4 M. 
2.6. Procedure for the Determination of Ziprasidone in Pharmaceuticals 
The ZPD content in capsules was determined by analyzing four capsules separately. The powder 
content of each one was shaken with 15 mL of methanol and then placed in an ultrasonic bath for 
15 min and finally diluted with methanol in a 25 mL calibrated flask. A portion of this solution was 
centrifuged at 3,000 rpm for 5 min and the supernatant was filtered through a filter paper. Different 
volumes (500–1,000 µL) of the filtrate were taken, to which 15 mL of buffer were added and finally 
diluted to 25 mL with methanol in a calibrated flask. A similar procedure was followed in the case of 
ZPD powder for injectable solutions. The ZPD concentration in the sample was determined by 
comparing the potential value measured with the calibration graph. 
Recovery studies were performed by adding different volumes (125–400 μL) of the ZPD standard 
solution to 1.0 mL of the pharmaceutical sample solution. Then, 15 mL of pH buffer were added and 
the solution was diluted to 25 mL with methanol in a calibrated flask. The samples were analyzed in 
triplicate using the procedure described above. 
2.7. Procedure for the Determination of Ziprasidone in Human Urine and Serum 
For the determination of ZPD in human urine samples the sample pH was adjusted to 4.6 with HCl 
and NaOH solutions. Serum samples were first deproteinized by adding a volume of 8% trichloroacetic 
acid solution to the same volume of serum. Then, the solutions were shaken in a vortex mixer for 30 s, 
allowed to settle for 20 min and centrifuged for 10 min at 1,200 rpm. The clear supernatant layer was 
filtered through a 0.45 µm Millipore filter and the pH was adjusted to 4.5 by adding 2 M NaOH. In the 
absence of urine and serum samples containing ZPD, known amounts of ZPD were added. The potential 
was measured and compared with calibration graphs made in pooled urines and pooled serum, 
respectively. 
3. Results and Discussion  
3.1. Influence of Membrane Composition 
Membranes of different compositions (Table 1), prepared as described in the Experimental section, 
were tested to optimize the membrane composition of the ZPD-electrode. Two plasticizers with 
different dielectric constants were used as membrane solvent, NPOE (ε = 23.9) and DOS (ε = 2.4), 




2:3 (v/v) methanol/pH buffer medium are shown in Figure 1. As can be seen, the membrane plasticized 
with NPOE showed higher potential span and lower detection limit, an effect that agrees with reports 
in the literature for other drug ISEs [42,43]. The difference observed between both membranes can be 
explained by the fact that the detection limit of ISEs based on dissolved ion-exchangers may be 
governed by the analyte ion activity present in the sample solution as a result of the distribution 
equilibrium of the ion-exchanger between the membrane and the solution [44]. The solubility of the 
ion-exchanger in the membrane generally increases as the polarity and dielectric constant of the 
membrane increases [45], which implies a lower concentration in the sample solution and therefore  
a lower detection limit. Taking these results into account NPOE was selected as plasticizer for   
further studies. 
Table 1. Composition of the membranes assayed. 
  Percentage (w/w) of components in membranes 
Membrane  PVC NPOE  DOS  ZPD-TPB 
A 33.0  66.0    1.0 
B 33.0    66.0  1.0 
C 32.3  64.7    3.0 
Two different ZPD-TPB ion exchanger concentrations in the membrane were tested (membranes A 
and C, respectively). As can be seen in Figure 1, the membrane containing the higher ion-exchanger 
concentration displayed a poorer potential response. Taking all this into account, membrane A was 
selected for further studies. 
Figure 1. Calibration graphs of ziprasidone obtained with membranes A, B and C. 
 
3.2. Influence of the pH 
The effect of pH on the electrode potential at various ZPD concentrations in the range   
8.0 × 10
−6–4.0 × 10
−5 M, was studied. The pH was varied by adding HCl or NaOH and the results are 
shown in Figure 2. As can be seen, the electrode potential was somewhat dependent on pH and 
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therefore the use of a pH buffer was thought convenient. A pH of 4.6 adjusted with 2 × 10
−1 M sodium 
Ac
-/AcH buffer solution was used for further studies. 
Figure 2. Influence of the pH on the electrode potential for different ziprasidone concentrations. 
 
3.3. Influence of the Mixed Solvent Composition 
Since ZPD is soluble in methanol and ethanol, the performance of the electrode was evaluated in 
hydroalcoholic media, i.e., methanol-water and ethanol-water mixtures of different ratios. All of them 
contained buffer solution of pH 4.6. Figure 3 shows the ZPD calibration graphs A-D determined in 
methanol/water 1:4, 2:3 and 3:2 (v/v), and ethanol/water 2:3 (v/v), respectively. By comparing the 
curves corresponding to different methanol contents, it is obvious that the best response was displayed 
when a methanol/water 2:3 (v/v) medium was used (curve B). When ethanol was used instead of 
methanol, the potential response was very poor. Accordingly to all this, a methanol/water 2:3 (v/v) 
medium was used for further studies. 
Figure 3. Calibration graphs in different media. (A) 1:4 (v/v) methanol/water; (B) 2:3 (v/v) 
methanol/water; (C) 3:2 (v/v) methanol/water; and (D) 2:3 (v/v) ethanol/water. 
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3.4. Validation of the Analytical Method 
The validation of the analytical method for the determination of ziprasidone based on the present 
ZPD-selective electrode was made following recommendations of the literature [46,47].  
3.4.1. Response Characteristics 
The slope and the limit of detection (LOD) of the selected electrode were determined by non-linear 
curve fitting of the corresponding calibration data to Equation (1). The values obtained for the range, 
linearity, slope, limit of detection and accuracy together with the response time of the electrode 
obtained from a dynamic calibration (Figure 4), are shown in Table 2. As can be seen, there was a 
Nernstian response over almost two concentration decades, with a low detection limit and a rapid 
response, even at low ZPD concentrations, was obtained. 













59.3 ± 1.8 
Limit of detection (M) ± RSD 
a  1.8 × 10
−5 ± 2.1 × 10
−6 
Accuracy 
c (%)  99.38 ± 0.37 
Response time (s) 
b t 95% ≤ 15 
Working pH range 
b 3.5–5.5 
Operational lifetime (days)  ≥ 40 
a mean of six calibrations. 
b ZPD concentration range of 1.6 × 10
−6–1.6 × 10
−4 M. 
c Recovery ± RSD (n = 10). 
Figure 4. Dynamic response of the electrode for ziprasidone concentrations of (1) 0 M;  
(2)  1.6 × 10
−6; (3) 3.2  ×  10
−6 M; (4) 7.2  ×  10
−6 M; (5) 1.1  ×  10
−5 M; (6) 1.9  ×  10
−5 M;   
(7)  2.7 × 10
−5 M; (8) 4.3  ×  10
−5 M; (9) 5.8  ×  10
−5 M; (10) 9.7  ×  10











































3.4.2. Repeatability and Reproducibility 
The repeatability and reproducibility of the calibration parameters were studied by making 
successive calibrations with the same membrane on the same day (n = 6), with the same membrane on 
different days (n = 6) and with different membranes (n = 3). The results obtained for the LOD were  
1.8 × 10
−5 ± 2.1 × 10
−6 M, 2.2 × 10
−5 ± 7.5 × 10
−6 M and 2.8 × 10
−5 ± 1.1 × 10
−5 M , respectively, and 
for the slopes, 59.3 ± 1.8, 58.4 ± 2.7 and 59.2 ± 2.8 mV per decade of concentration, respectively.  
In all these aspects, a reasonably good reproducibility was obtained. 
3.4.3. Electrode Lifetime 
The electrode lifetime was obtained by periodically performing calibration graphs for ZPD and 
calculating the response parameters. The ZPD selective electrode worked for at least 40 days, during 
which time no appreciable change in the calibration characteristics or response time was observed. 
After this time, the slope of the electrode started to decrease. 
3.4.4. Selectivity 





lactose, saccharose, urea, uric acid, hipuric acid, amoxicillin, cimetidine, ofloxacin, diclofenac, tenoxicam, 
lansoprazole, loracepam, carbamazepine, fluoxetine, biperidene, haloperidol, and ranitidine. This list 
includes species frequently present in pharmaceuticals and biological fluids and drugs that could be 
administered at the same time as ZPD. Solutions of these compounds were prepared in methanol and 





2+, glucose, lactose, saccharose, urea, uric acid, hipuric acid, 
amoxiciline, cimetidine, ofloxacin, diclofenac, tenoxicam, lansoprazole, loracepam, carbamazepine 
and ranitidine at concentrations below 3 × 10
−4 M. The electrode displayed a near Nernstian response 
to fluoxetine, haloperidol and biperidene and so the selectivity coefficients of these three species were 
determined by applying the separate solution method [48]. The values obtained were 1.5, 0.5 and 2.4, 
respectively. 
3.5. Analytical Applications 
In order to demonstrate the applicability of the proposed method to the determination of ZPD, the 
method was applied to its determination in pharmaceuticals and human urine and serum. Two different 
pharmaceutical dosage forms of ZPD were analysed following the method described in the 
Experimental (Table 3). In the absence of a reference method for the analytical determination of ZPD 
in the literature, recovery studies were carried out (Table 3), providing quantitative recoveries between 
99.3 and 101.7% in all the cases.  
 




Table 3. Determination of ziprasidone in pharmaceuticals. 
Sample Labelled 








c (%)  % Bias 
Zeldox 
capsules 
20.00  20.02 ± 0.54 
b 0.10 
5.86 25.82 
b  99.3 ± 0.5  −0.68 
11.73 31.93 
b  101.7 ± 4.1  1.70 
18.70 38.68 
b  99.9 ± 3.5  −0.11 
Zeldox 
injectables 
20.00  20.39 ± 1.09 
b 1.90 
5.86 25.87 
b  100.2 ± 0.7  0.17 
11.73 31.80 
b  100.6 ± 0.2  0.59 
18.70 38.66 
b  99.8 ± 0.1  −0.21 
a ZPD mg/capsule or injectable. 
b Average of three experiments. 
c Mean ± RSD (n = 4). 
 
For the determination of ZPD in human urine, previous calibrations using different urines were 
made. No significant differences between the corresponding calibration parameters were found. 
Therefore, a calibration made using pooled urine samples was used for the determination of ZPD in 
different samples. A similar procedure was used for the determination of ZPD in serum. The results 
obtained are shown in Table 4. Good recoveries were obtained for the determination of ZPD in both 
types of biological sample. 
Table 4. Determination of ziprasidone in human urine and serum. 
Sample Amount  added Found 
c Recovery
c ± RSD (%)  % Bias 
Urine 1  2.80
a  2.70  96.4 ± 1.2  −3.57 
Urine 2  4.70
a  4.73  100.6 ± 0.5  0.64 
Urine 3  8.30
a  8.08  97.4 ± 2.0  −2.65 
Urine 4  12.0
a  12.3  102.5 ± 1.4  2.50 
Serum 1  0.90
b  0.93  103.3 ± 1.1  3.33 
Serum 2  2.80
b  2.79  99.6 ± 0.3  −0.36 
Serum 3  6.50
b  6.49  99.8 ± 0.2  −0.15 
Serum 4  15.6
b  15.88  101.8 ± 0.9  1.79 
a ZPD mg/L urine. 
b ZPD µg/mL serum. 
c Average of five experiments. 
 
The systemic bioavailability of ZPD administered intramuscularly is 100% and 60% if it is 
administered orally. After a single dose intramuscular administration, the peak serum concentration 
typically occurs at about 60 minutes after the dose is administered, or earlier. In the case of an oral 
administration, the peak serum concentration is reached from 2 to 6 hours after the administration of 
therapeutic doses and approximately 44% of the total serum ZPD remains unchanged. The normal 
therapeutic dose of ZPD recommended for adults is between 40 and 160 mg/day and from 1 to 4% is 
excreted unchanged in the urine after its administration. Taking into account these data and the results 
obtained, it can be concluded that the determination of ZPD in human urine and serum is feasible using 
the present electrode being this method very useful for routine clinical analysis. 
3.6. Advantages of the Proposed Method 
The potentiometric method proposed shows some advantages over the other electroanalytical method 




method requires electrode polishing before each experiment, no electrode pre-treatment is needed in 
the present potentiometric method. Variations of the pH of the medium also have less influence in the 
potentiometric method, which is not affected by the presence of some other drugs and compounds 
frequently present in pharmaceuticals and biological fluids. Finally, while both methods are useful for 
pharmaceuticals and serum analysis, the potentiometric method was also applied to urine analysis. 
4. Conclusions 
The presented ISE provides a rapid, sensitive, reproducible and precise method for the 
potentiometric determination of ziprasidone in mixed solvents. The new electrode could be very useful 
in pharmaceutical analysis in the absence of a existing reference method for ziprasidone determination. 
The electrode can also be used to determine ziprasidone in human urine and serum.  
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